People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| New Frontier Bio, Inc. | — | Biotech / Pharma | Series A | $9.2M | $1.7M | 2024 |
Kevin Kong at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kevin Kong on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen Smith | 1 | 17 |
| James Linton | 1 | 2 |
| James P. Linton | 1 | 2 |
| Vincent Mai | 1 | 1 |
| Kaiyuan Wang | 1 | 1 |
| Serge Schoen | 1 | 1 |
| Kevin P. Kong | 1 | 1 |
| Vincent P. Mai | 1 | 1 |
| Kaiyuan P. Wang | 1 | 1 |
| Serge P. Schoen | 1 | 1 |
| Stephen Kennedy Smith | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.